A Canadian researcher will use a newly granted Lupus Canada Catalyst Award — with one year of funding totaling $40,000 CAD (around $29,300) — for a study focused on better understanding the role of an inflammation marker in predicting treatment responses in people with lupus nephritis. Lupus nephritis is one…
News
Galapagos officially has launched a Phase 2 clinical trial that will test its oral therapy GLPG3667 — designed to ease disease severity in people with systemic lupus erythematosus (SLE) — at a half dozen sites in the U.S. The first participant has been randomized, or assigned to a treatment…
To raise money to battle lupus and increase awareness about the chronic autoimmune disorder, Allsup, which provides Social Security disability assistance, is again supporting the Lupus Foundation of America’s (LFA) annual Walk to End Lupus Now in St. Louis. Registration is required for the in-person event, set…
AlloNK, an off-the-shelf experimental natural killer (NK) cell therapy being developed by Artiva Biotherapeutics, soon will enter clinical testing, in combination with rituximab, for systemic lupus erythematosus (SLE) patients with active lupus nephritis. This follows the approval of the company’s investigational new drug application by the U.S.
Immpact Bio has been cleared in the U.S. to start testing its cell therapy IMPT-514 in people with active systemic lupus erythematosus (SLE) that is refractory, or resistant to treatment. The clearance by the U.S. Food and Drug Administration “marks a pivotal milestone for our autoimmune disease clinical…
PALIZADE, a Phase 2b clinical trial of Kezar Life Sciences’ investigational therapy zetomipzomib, is still enrolling systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe lupus complication that causes kidney damage. The launch of the placebo-controlled PALIZADE trial (NCT05781750) earlier this year followed the completion…
Racial discrimination was found to be associated with increased inflammation among Black women with systemic lupus erythematosus (SLE) in a recent study. Each experience of racial discrimination was tied to a nearly 4% increase in the levels of C-reactive protein (CRP), an inflammation marker, in the bloodstream, the findings…
Disparities in lupus care and outcomes in the U.S. are influenced by structural and social determinants such as race, ethnicity, socioeconomics, education, and healthcare access. These are the findings of a study by the Lupus Foundation of America (LFA) through its Addressing health Inequities in Minorities (AIM)…
The Lupus Foundation of America has announced this year’s winners of the Gina M. Finzi Memorial Student Summer Fellowship Program, designed to support students working in lupus research. Each award, worth $4,000, includes mentorship by an experienced researcher in the field of lupus. Winners, all young scientists, are pursuing…
The Lupus Research Alliance (LRA) has awarded a $3-million grant to a multidisciplinary research group working to identify drivers of lupus nephritis, a serious complication of lupus characterized by kidney damage, in children with the autoimmune disease. Elena Hsieh, MD, an associate professor at the University of Colorado…
Recent Posts
- I’m learning it’s OK to not be OK while living with lupus
- FDA approves Saphnelo Pen for at-home lupus treatment
- Advocates urge community action during Lupus Awareness Month
- A message to newly diagnosed lupus patients: You will learn
- Spring brings warmer weather, and a bigger risk of a lupus flare-up